In the non-inferiority, RATIONALE-301 study presented by Dr. Masatoshi Kudo, Single agent Tislelizumab (TIS), an anti-PD-1 monoclonal antibody, showed comparable efficacy to sorafenib with a favourable safety profile in patients with unresectable #HCC. In its final analysis, RATIONALE-301 met its primary endpoint of OS non-inferiority (mOS: 15.9 mo [TIS] vs 14.1 mo [SOR];HR: 0.85.TIS was associated with higher ORR but shorter PFS. The incidence of adverse events at any grade and at ≥grade 3 were lower with tislelizumab vs sorafenib.
.png)